Related Experiment Video
Updated: Nov 29, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Mendelian randomization study shows no causal effects of serum urate levels on the risk of MS
Adil Harroud1, J Brent Richards1, Sergio E Baranzini2
1From the Department of Neurology (A.H., S.E.B.), University of California San Francisco, California; Weill Institute for Neurosciences (A.H., S.E.B.), University of California San Francisco, California; Centre for Clinical Epidemiology (J.B.R.), Department of Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada; Department of Human Genetics (J.B.R.), McGill University, Montreal, Quebec, Canada; Department of Medicine (J.B.R.), McGill University Montreal, Quebec, Canada; Department of Epidemiology (J.B.R.), Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada; Department of Twin Research and Genetic Epidemiology (J.B.R.), King's College London, United Kingdom; Institute for Human Genetics (S.E.B.), University of California San Francisco, California; and Bakar Computational Health Sciences Institute (S.E.B.), University of California San Francisco, California.
Objective:
To examine whether lifelong genetically increased serum urate levels, a potent antioxidant, contribute to MS susceptibility using Mendelian randomization (MR).
Methods:
This 2-sample MR study included 25 independent genetic variants strongly associated with serum urate levels in a genome-wide association study meta-analysis of 140,949 individuals. Effects on the risk of MS were assessed with summary statistics from 3 large-scale MS genetic data sets totaling 61,667 MS cases and 86,806 controls from the International MS Genetic Consortium. Multiple sensitivity analyses were performed to evaluate the assumptions of MR and remove potentially pleiotropic variants.
Results:
Using inverse-variance weighted MR, we found no evidence for a causal effect of serum urate level on the risk of MS in any of the cohorts (MS1: OR 0.99 per each mg/dL unit increase in urate, 95% CI 0.89-1.08, p = 0.76; MS2: OR = 0.99, 95% CI 0.89-1.11, p = 0.90; MS3: OR = 1.00, 95% CI 0.98-1.2, p = 0.91). Pleiotropy robust MR methods yielded consistent estimates.
Conclusion:
This MR study does not support a clinically relevant causal effect of serum urate levels on the risk of MS.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Randomized Experiments
Simple randomization
Simple...
What is an Experiment?
Serum Studies: Renal Function Tests
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration